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The mutation rate of codon 43 was 57.5% (61/106). The
results of HRM of the 50 strains were identical to those of
sequencing.
Conclusion: Mutation in rpsL gene is the important
molecular mechanism of streptomycin resistance in
M.tuberculosis. High-resolution melting method is a
sensitive in-tube methodology to screen for mutations of
streptomycin resistance in M.tuberculosis. HRM analysis
using a dsDNA dye provides a useful tool and is applicable for
rapid and high-throughput screening of rpsL gene mutations
in M.tuberculosis.
Free Paper Presentation 2 Hepatitis B
OL-010 Biochemical, immunological and virological
proﬁles of, and differential diagnosis between
patients with acute hepatitis B and chronic
hepatitis B with acute ﬂare
Y.N. Han, Q. Tang, W. Zhu, X.Q. Zhang, L.Y. You. Research
Unit of Liver Disease, Shanghai No. 8 People’s Hospital,
Shanghai 200235, China
Background and Aim: In areas of intermediate or high
prevalence of chronic hepatitis B virus (HBV) infection,
it is difﬁcult to distinguish acute hepatitis B (AHB) from
chronic hepatitis B with an acute ﬂare (CHB-AF) in patients
whose prior history of HBV infection was unknown. The
Immunoglobulin M antibody against hepatitis B core antigen
has been used as a differentiation indicator. The present
study aimed to screen other laboratory parameters to
construct a more efﬁcient joint diagnosis method.
Methods: A retrospective and prospective study was carried
out in patients ﬁrst clinically presenting as HBV-related
acute hepatitis to sort out the individuals with acute self-
limited hepatitis B (ASL-HB). Laboratory testing proﬁles
were compared between patients with ASL-HB and CHB-
AF. The sensitivity, speciﬁcity, accuracy, positive predictive
values, and negative predictive values for diagnosing AHB
of the parameters closely associated with ASL-HB were
evaluated.
Results: Signiﬁcant differences were observed between
patients with ASL-HB and CHB-AF in laboratory proﬁles,
and the differences showed in the increased levels of
serum HBVDNA, HBV e antigen (HBeAg), alpha-fetoprotein
(AFP) and anti-HBc IgM. Furthermore, It was found that
the population number of ASL-HB patients was signiﬁcantly
higher than that of CHB-AF in those with low levels positive
HBeAg (S/CO < 20) (42.7% vs 13.5%), but this was not found
in HBeAg negative group (49.3% vs 45.9%). For predicting
ASL-HB, the sensitivity and speciﬁcity of single 1:10 000
anti-HBc IgM were respectively 96.2% and 93.1%. Combining
anti-HBc IgM with HBVDNA, or and HBeAg could improve the
dignostic power. The combination of anti-HBc IgM, HBVDNA,
and HBeAg had a positive predictive value of 98.9% and a
negative predictive value of 100.0%, similar to those of the
combination of IgM anti-HBc and HBVDNA. AFP added to
either combination groups further increased the positive
predictive value. Both the positive predictive value and
negative predictive value of the combination of IgM anti-
HBc, HBVDNA and AFP were 100.0%.
Conclusions: (1) There are signiﬁcant differences in
biochemical, immunogical and virological aspects between
ASL-HB and CHB-AF. (2) Among several joint diagnostic
methods, IgM anti-HBc combining HBVDNA and AFP is the
most effective and practical in distinguishing ASL-HB from
CHB-AF. (3) A low HBeAg level is more helpful than negative
HBeAg in differential diagnosis between ASL-HB and CHB-AF.
(4) Patients with a high level of IgM anti-HBc, serum AFP
level >5×URL could rule out a probability of ASL-HB.
OL-011 Positive serum hepatitis B e antigen associated
with higher risk of early recurrence and poorer
survival in patients after curative resection of
hepatitis B-related hepatocellular carcinoma
H.C. Sun1 *, W. Zhang1, L.X. Qin1, B.H. Zhang1, Q.H. Ye1,
L. Wang1, N. Ren1, P.Y. Zhuang1, X.D. Zhu1, J. Fan1,
Z.Y. Tang1. 1Liver Cancer Institute and Zhongshan Hospital,
Fudan University, Shanghai, China
Background and Aim: To study the impact of hepatitis B
e antigen on tumor recurrence and patients’ survival after
curative resection of hepatocellular carcinoma.
Methods: 203 patients with small hepatocellular carcinomas
(3 cm) undergone curative resection were divided
into HBeAg-positive group and HBeAg-negative group.
Clinicopathological factors and postoperative outcomes
were compared between groups, and risk factors for survival
and recurrence were studied.
Results: The median follow-up time is 32.9 months.
Those with negative HBeAg were better in both 5-year
overall survival (76% vs 53.9%, hazards ratio (HR): 2.363,
95%CI:1.335 4.181, P= 0.002) and 5-year disease-free
survival (52.9% vs 37.4%, HR: 1.603, 95%CI: 1.00 2.561,
P= 0.046).There was no signiﬁcant difference in operative
morbidity and tumor factors between the two groups,
but younger age, higher serum alanine aminotransferase
level, and more macronodular cirrhosis were found in
HBeAg-positive group. Multivariate analysis revealed that
age >50 years, HBeAg positivity and macronodular cirrhosis
were independent factors for overall survival, and HBeAg
positivity and multiple tumor nodules were independent
factors for disease-free survival. Positive serum HBeAg
associated with a higher risk of early recurrence (within
1 year).
Conclusions: Positive HBeAg associated with a higher risk
of early recurrence and poorer survival of patients after
curative resection of small HCC.
OL-012 HepG2.2.15 can induce the expression of PD-1
on T-cell: may be a mechanism of immune
tolerance in HBV infection
J. Chen*, X.J. Wu, Y.H. Wang, Y. Wang, J. Li, M. Yu,
N.L. Zhang, G.Q. Wang. Department of Infection Disease,
Peking University First Hospital, Beijing 10034, China
Background and Aims: To investigate the effect of
HepG2.2.15 a cell line transfected HBV geneome in
inducing PD-1 (Programmed cell death-1) expression on
T-cell, and the function of PD-1 on T-cell.
Methods: HepG2.2.15 were co-cultured with Jurkat cells,
which a kind of T lymphocyte. The PD-1 expression was
detected by ﬂow cytometry (FCM); Blocking test by adding
anti-PD-1 antibody in the experiment; Cytokines in culture
supernatant of blocking groups and control groups were
measured by enzyme-labeled immunosorbent assay (ELISA);
Cytotoxic test of T-cells in blocking groups and controls
were measured by methyl thiazolyl tetrazolium (MTT).
Results: The PD-1 expression on T-cells was induced
by HepG2.2.15, the expression rate is 17.43±5.6%
(control is 1.22±0.2%); The cytokines IL-2 level
(202.9±53.0 pg/ml), INF-g level (88.6±4.6 pg/ml) and IL-
10 level (63.7±13.4 pg/ml) in culture supernatant of
blocking groups were signiﬁcant higher than that of controls
(IL-2, 102.9±53 pg/ml, INF-g, 39.3±4.2 pg/ml and IL-10,
34.6±13.7 pg/ml, respectively. p < 0.05); The cytotoxic test
(OD value) was markedly higher in bloking group (0.29±0.06)
than that of control group (19±0.09, p < 0.05).
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Conclusion: The PD-1 expression on T-cells can be induced
by HBV infected cells HepG2.2.15, and cytokines
expression and cytotoxic test were recovered by blocking
PD-1/PDL-1 interaction. So, HBV infection may regulate the
PD-1 expression and function, leading to immune tolerance
during HBV infection.
OL-013 Identiﬁcation and signiﬁcance of pre-S deletion
mutants in human and woodchuck HBV-related
hepatocellular carcinoma
H.C. Wu1 *, K. Abe2, Y.C. Lo3, I.J. Su1. 1Division of Clinical
Research, National Health Research Institutes, Tainan,
Taiwan, 2.Department of Pathology, National Institute of
Infectious Diseases, Tokyo, Japan, 3Graduate Institutes of
Basic Medicine Sciences, National Cheng Kung University
College, Tainan, Taiwan
Background and Aims: Hepatitis B virus (HBV) infection
has been closely associated with the development of
hepatocellular carcinoma (HCC). In the past few years,
we have identiﬁed and constructed two major types of
pre-S mutants in ground glass hepatocytes, Type I and
Type II GGHs, which pre-S mutants with deletions over
the pre-S1 region (nt 3040 to 3111) and pre-S2 region
(nt 4 to 57), respectively. The mutant pre-S proteins are
retained in endoplasmic reticulum (ER) and induce ER
stress and DNA damage. Pre-S2 mutant transgenic mice can
develop dysplasia of hepatocytes and HCC. Furthermore,
the presence of pre-S mutants can predict the development
of HCC. Therefore, pre-S mutants are now considered to
be viral oncoproteins. The status of pre-S mutants in HCC
tissues and its signiﬁcance has not yet been clariﬁed.
Materials and Methods: The prevalence of pre-S mutants
in HBV-related HCCs was studied on tumor tissues obtained
from 34 adults and 19 childhood patients. Tumor tissues from
8 Woodchuck hepatitis virus (WHV)-infected HCCs were also
studied for comparison.
Results: The prevalence rate of pre-S mutants in HCC
tissues from human adults, children, and woodchucks
were 55.88%, 89.74% and 62.50%, respectively. The pre-
S2 mutants prevailed over the pre-S1 deletion mutants
in human HCC, 84.21% in adults and 88.24% in children,
whereas only pre-S1 mutants (100%) were detected in
Woodchuck HCC tissues.
Conclusion: Given the high prevalence of pre-S2 mutants in
human HCC tissues, pre-S2 mutant may play a major role
in human HBV hepatocarcinogenesis, while pre-S1 mutants-
induced pathway such as ER stress signals might play a
major role in woodchuck HCC. The high prevalence of pre-
S2 mutant is childhood HCC is interesting and should shed
light on HBV hepatocarcinogenesis, considering the high
cirrhosis rate and the rapid development of HBV-related
HCC.
OL-014 Prevalence of HBV infection and efﬁcacy of
vaccination in rural children in Mongolia
Y. Dahgwahdorj *, N. Horolsuren, B. Bayarmagnai,
S. Chinzorig, B. Baigal. Health Sciences University of
Mongolia, Mongolia
Introduction: Before 1990, prevalence of HBV infection
was approximately 15% in whole population of Mongolia.
Therefore, there was introduced HBV vaccination as
mandatory immunization since 1991. But, by the study
conducted 5 years ago, the efﬁcacy of HBV vaccination
in the rural nomadic children was signiﬁcantly lower than
urban. So, government implemented some measures for
increase the efﬁcacy of HBV vaccination in rural.
Aim: To study the prevalence of HBV infection and efﬁcacy
of HBV vaccination of children living in provincial centre
and rural nomadic.
Method and subjects: There were selected randomly and
matching age and sex 146 children from provincial centre
(Selenge province), 79 from rural nomadic living population
(Ongon somon of Suhbaatar province) in 2006 2007. In all
serum of subjects were analyse for HBsAg and anti-HBs.
Results: The results are shown in the table.
Age Anti-HBs (%) HBsAg (%)
Selenge Ongon Selenge Ongon
1 76.5 55.6 0 0
3 57.9 90.0 0.5 0
5 31.6 50.0 10.5 0
7 36.8 10.0 0 0
9 35.3 20.0 5.9 20.0
11 30.0 10.0 5.0 10.0
13 4.5 10.0 0 10.0
15 15.0 20.0 10.0 20.0
Mean 34.6 32.9 4.6 7.6
Conclusions: 1. After 15 years of the vaccination the
prevalence of HBV infection decreased to 2 3 fold. 2. The
efﬁcacy of HBV vaccination in rural nomadic children has
possibilities as urban or in another developed country’s
children.
OL-015 A pharmacogenomics approach to predict the
efﬁcacy of HBeAg-positive chronic hepatitis B
patients with pegylated interferon treatment
Y.C. Hwang1, G.K.K. Lau2, J.H. Kao3, W.L. Chuang4,
C.Y. Peng5, X.X. Zhang6, M. Wan7, K.H. Liang1, E. Chao8,
E.Y. Chen1,8 *. 1Vita Genomics, Inc., Taipei County, Taiwan,
2Department of Medicine, Queen Mary Hospital, University
of Hong Kong, Hong Kong SAR, China, 3Hepatitis Research
Center, National Taiwan University, Taipei, Taiwan,
4Department of Internal Medicine, Kaohsiung Medical
University Hospital, Taiwan, 5China Medical University
Hospital, Taichung City, Taiwan, 6Ruijin Hospital, Shanghai
Jiao Tong University, Shanghai, China, 7Changhai Hospital,
Second Military Medical University, Shanghai, China,
8Shanghai GeneCore Biotechnologies, Shanghai, China
Background: In hepatitis B e antigen (HBeAg)-positive
patients, the HBeAg seroconversion rate reaches 32% when
treated with the pegylated interferon alfa (Peg-IFN). There
are many other anti-viral drugs available for treating chronic
hepatitis B (CHB) patients. It would therefore be beneﬁcial
to include a pre-treatment evaluation to ﬁnd which
patients should be treated with interferon. For the goal
of individualizing anti-HBV therapy, a pharmacogenomics
study to screen a genetic algorism using human genotypes
to predict the responsiveness of HBeAg-positive patients
who were under Peg-IFN treatments has been developed.
Methods: In this study, single nucleotide polymorphisms
(SNPs) were selected from genes involved in pathways
related to IFN signaling and immunomodulation. More than
250 SNPs from 30 candidate genes were genotyped with
samples collected from 180 Peg-IFN treated CHB patients.
After a serious of computer-aided analysis, a total of 30
polymorphisms were found to be strongly associated with
the responsiveness. A panel of SNPs was further selected to
predict the treatment outcomes.
Results: We discovered genetic predisposition factors which
can differentiate responders from non-responders in PEG-
IFN treated CHB patients. One of the algorithms developed
can use SNPs from a few genes to predict the treatment
